Cited by 52Cellular transport and secretionAngiogenesis and VEGF in CancerAutophagy in Disease and Therapy

Protein kinase LKB1 promotes RAB7-mediated neuropilin-1 degradation to inhibit angiogenesis

Open access
Okon, Imoh S., Coughlan, Kathleen A., Zhang, Cheng, Moriasi, Cate, Ding, Ye, Song, Ping, Zhang, Wencheng, Li, Guangpu +1 more·2014·Journal of Clinical Investigation

Abstract

After internalization, transmembrane receptors (TMRs) are typically recycled back to the cell surface or targeted for degradation. Efficient TMR trafficking is critical for regulation of several processes, including signal transduction pathways, development, and disease. Here, we determined that trafficking of the angiogenic receptor neuropilin-1 (NRP-1) is abrogated by the liver kinase B1 (LKB1), a serine-threonine kinase of the calcium calmodulin family. We found that aberrant NRP-1 expression in tumor cells from patients with lung adenocarcinoma is associated with decreased levels of LKB1. In cultured lung cells, LKB1 accentuated formation of a complex between NRP-1 and RAB7 in late endosomes. LKB1 specifically bound GTP-bound RAB7, but not a dominant-negative GDP-bound form of RAB7, promoting rapid transfer and lysosome degradation of NRP-1. siRNA-mediated depletion of RAB7 disrupted the transfer of NRP-1 to the lysosome, resulting in recovery of the receptor as well as increased tumor growth and angiogenesis. Together, our findings indicate that LKB1 functions as a RAB7 effector and suppresses angiogenesis by promoting the cellular trafficking of NRP-1 from RAB7 vesicles to the lysosome for degradation. Furthermore, these data suggest that LKB1 and NRP-1 have potential as therapeutic targets for limiting tumorigenesis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci75371

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In the Keap1Fl/Fl;PtenFl/Fl GEMM, deleting both Keap1 and Pten produced immunologically cold tumors resembling those with Lkb1 mutation.

    “In a conditional GEMM of LUAD (Keap1Fl/Fl;PtenFl/Fl), co-deletion of Keap1 and Pten resulted in immunologically cold tumors, akin to Lkb1-mutant NSCLC141.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Okon, I. S., Coughlan, K. A., Zhang, C., Moriasi, C., Ding, Y., Song, P., Zhang, W., Li, G., & Zou, M.-H.
Affiliations
  • University of Oklahoma (US)
  • Shandong University (CN)
Corresponding author
Zou, Ming-Hui
Venue
Journal of Clinical Investigation
Published
2014-09-02
Volume
124
Issue
10
Pages
4590-4602
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2073594821
Cited by
52
References
56
Citations by year
2026: 1 · 2025: 4 · 2024: 1 · 2023: 5 · 2022: 6 · 2021: 6 · 2020: 5 · 2019: 7 · 2018: 3 · 2017: 6 · 2016: 5 · 2015: 2
FWCI
2.16
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (HL080499, HL074399)
  • National Institute on Aging (AG047776, R01AG047776)
  • National Heart, Lung, and Blood Institute (HL-105157, R01HL105157, HL 079584, R01HL079584, HL110488, HL-080499, HL096032, HL074399, R01HL074399, R01HL080499, HL-089920, R01HL110488, R01HL089920, R01HL096032)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
Keywords
LKB1, neuropilin-1, Rab7, angiogenesis, receptor degradation, lysosomal degradation, late endosomes, receptor trafficking, lung adenocarcinoma, tumor growth, therapeutic target
MeSH terms
Adenocarcinoma of Lung, rab7 GTP-Binding Proteins, AMP-Activated Protein Kinase Kinases, Adenocarcinoma, Aged, Animals, Cell Membrane, Female, Humans, Lung, Lung Neoplasms, Lysosomes, Male, Middle Aged, Mutation, Neovascularization, Pathologic, Signal Transduction, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Protein Serine-Threonine Kinases, rab GTP-Binding Proteins, RNA Interference, RNA, Small Interfering, Neuropilin-1, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Mice, AMP-Activated Protein Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review